Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est

Benzinga Newsdesk www.benzinga.com Positive 75.6%

Neg 0% Neu 0% Pos 75.6%

Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.

Comments

No comments yet. Be the first!